Silencing of x-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1682-1692

  Liu, Y ^a   Wu, X ^a   Sun, Y ^a   Chen, Fuhui ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Gemcitabine; Gene silencing; Non Small Cell Lung Cancer (NSCLC); Paclitaxel; siRNA; X Linked Inhibitor of Apoptosis (XIAP)

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; GEMCITABINE; PACLITAXEL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; X LINKED INHIBITOR OF APOPTOSIS GENE;

EID: 80155130040     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900510     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Beadsmoore CJ, Screaton NJ: Classification, staging and prognosis of lung cancer. Eur J Radiol 2003; 45: 8-17.
3. Cortés-Funes H: New treatment approaches for lung cancer and impact on survival. Semin Oncol 2002; 29(3 suppl 8): S26-S29.
4. Bunn PA Jr, Vokes EE, Langer CJ, et al: An update on North American randomized studies in non-small cell lung cancer. Semin Oncol 1998; 25: 2-10.
5. Wang G, Reed E, Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004; 12: 955-965.
6. Ramalingam S, Belani CP: State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31(1 suppl 1): 68-74.
7. Gridelli C, Rossi A, Maione P: Treatment of nonsmall cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003; 22: 6629-6638.
8. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
9. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70.
10. Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414-7430.
11. Hengartner MO: The biochemistry of apoptosis. Nature 2000; 407: 770-776.
12. Deveraux QL, Reed JC: IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
13. Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
14. Zhang XD, Zhang XY, Gray CP, et al: Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339-7348.
15. Stennicke HR, Ryan CA, Salvesen GS: Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci 2002; 27: 94-101.
16. Holcik M, Korneluk RG: XIAP, the guardian angel. Nat Rev Mol Cell 2001; 2: 550-556.
17. Holcik M, Gibson H, Korneluk RG: XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-261.
18. Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta A, et al: The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 2004; 9: 705-715.
19. Cummins JM, Kohli M, Rago C, et al: X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64: 3006-3008.
20. Ravi R, Fuchs EJ, Jain A, et al: Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res 2006; 66: 1730-1739.
21. Iwasa T, Okamoto I, Suzuki M, et al: Radiosensitizing effect of YM155, a novel smallmolecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-6504.
22. Cheng YJ, Jiang HS, Hsu SL, et al: XIAPmediated protection of H460 lung cancer cells against cisplatin. Eur J Pharmacol 2010; 627: 75-84.
23. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
24. Ferreira CG, Tolis C, Span SW, et al: Druginduced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000; 6: 203-212.
25. Zhu H, Guo W, Zhang L, et al: Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA. Cancer Biol Ther 2005; 4: 393-397.
26. Ferreira CD, Epping M, Kruyt FA, et al: Apoptosis: target of cancer therapy. Clin Cancer Res 2002; 8: 2024-2034.
27. Pommier Y, Sordet O, Antony S, et al: Apoptosis defect and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-2949.
28. Liu JR, Opipari AW, Tan L, et al: Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62: 924-931.
29. Srinivasula SM, Ashwell JD: IAPs: what's in a name? Mol Cell 2008; 30: 123-135.
30. Broemer M, Meier P: Ubiquitin-mediated regulation of apoptosis. Trends Cell Biol 2009; 19: 130-140.
31. Bilim V, Kasahara T, Hara N, et al: Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrugresistant TCC in vitro. Int J Cancer 2003; 103: 29-37.
32. Hofmann HS, Simm A, Hammer A, et al: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 2002; 128: 554-560.
33. Esposito L, Conti D, Ailavajhala R, et al: Lung cancer: are we up to the challenge? Curr Genomics 2010; 11: 513-518.